A phase 3, randomised, double-blind, placebo-controlled, 52-week study to evaluate the efficacy and safety of once-weekly PB-119 as add-on to metformin in patients with type 2 diabetes in China

被引：0
|
作者：
Xu, M. [1 ]
机构：
[1] Pegbio Biomed Co, Suzhou, Peoples R China
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
638
引用
收藏
页码：S321 / S322
页数：2
相关论文
共 50 条
  • [21] Long-term safety and efficacy of linagliptin as add-on therapy to basal insulin in patients with type 2 diabetes: a 52-week randomised, placebo-controlled trial
    Yki-Jarvinen, H.
    Rosenstock, J.
    Duran-Garcia, S.
    Pinnetti, S.
    Bhattacharya, S.
    Thiemann, S.
    Patel, S.
    Woerle, H-J
    DIABETOLOGIA, 2012, 55 : S9 - S9
  • [22] Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial
    Gao, Leili
    Cheng, Zhifeng
    Su, Benli
    Su, Xiuhai
    Song, Weihong
    Guo, Yushan
    Liao, Lin
    Chen, Xiaowen
    Li, Jiarui
    Tan, Xingrong
    Xu, Fangjiang
    Pang, Shuguang
    Wang, Kun
    Ye, Jun
    Wang, Yuan
    Chen, Lili
    Sun, Jingfang
    Ji, Linong
    DIABETES OBESITY & METABOLISM, 2023, 25 (03): : 785 - 795
  • [23] Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
    Clifford J Bailey
    Jorge L Gross
    Delphine Hennicken
    Nayyar Iqbal
    Traci A Mansfield
    James F List
    BMC Medicine, 11
  • [24] Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
    Bailey, Clifford J.
    Gross, Jorge L.
    Hennicken, Delphine
    Iqbal, Nayyar
    Mansfield, Traci A.
    List, James F.
    BMC MEDICINE, 2013, 11
  • [25] A randomised, double-blind, placebo-controlled, 39 week trial of ITCA 650 as add-on therapy in type 2 diabetes
    Baron, M. A.
    Buse, J.
    Azeem, R.
    Kjems, L.
    Rosenstock, J.
    DIABETOLOGIA, 2015, 58 : S55 - S55
  • [26] Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial
    Weng, Jianping
    Zeng, Longyi
    Zhang, Yuwei
    Qu, Shen
    Wang, Xueying
    Li, Ping
    Fu, Liujun
    Ma, Boqing
    Ye, Shandong
    Sun, Jiao
    Lu, Weiping
    Liu, Zhiwen
    Chen, Daoxiong
    Cheng, Zhifeng
    Liu, Haiyan
    Zhang, Tao
    Zou, Jianjun
    DIABETES OBESITY & METABOLISM, 2021, 23 (08): : 1754 - 1764
  • [27] Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 3b trial
    Gao, Fei
    Lv, Xiaofeng
    Mo, Zhaohui
    Ma, Jianhua
    Zhang, Qiu
    Yang, Gangyi
    Liu, Weijuan
    Li, Quanmin
    Zhou, Jian
    Bao, Yuqian
    Jia, Weiping
    DIABETES OBESITY & METABOLISM, 2020, 22 (12): : 2375 - 2383
  • [28] Erratum to: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
    Clifford J Bailey
    Jorge L Gross
    Delphine Hennicken
    Nayyar Iqbal
    Traci A Mansfield
    James F List
    BMC Medicine, 11
  • [29] A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 3 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ANAGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES
    Yang, H. K.
    Lee, S. H.
    Min, K. W.
    Park, S. W.
    Chung, C. H.
    Park, K. S.
    Choi, S. H.
    Song, K. -H.
    Kim, D. -M.
    Lee, M. -K.
    Sung, Y. A.
    Baik, S. H.
    Kim, I. J.
    Cha, B. -S.
    Park, J. H.
    Ahn, Y. B.
    Lee, I. -K.
    Yoo, S. -J.
    Kim, J. T.
    Park, I. B.
    Park, T. S.
    Yoon, K. -H.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S149 - S150
  • [30] Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial
    Sone, Hirohito
    Kaneko, Tatsuroh
    Shiki, Kosuke
    Tachibana, Yoshifumi
    Pfarr, Egon
    Lee, Jisoo
    Tajima, Naoko
    DIABETES OBESITY & METABOLISM, 2020, 22 (03): : 417 - 426
12345